Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05922735
Other study ID # ANRS 0297s MonVIP
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2023
Est. completion date February 1, 2025

Study information

Verified date June 2023
Source ANRS, Emerging Infectious Diseases
Contact Simon AMADOR PAZ
Phone 01 53 94 80 78
Email simon.amador-paz@anrs.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a cohort, non-health product, non-interventional biomedical research, multi-centric, to determine the seroprevalence of mpox infection in the population of people living with HIV and in PrEP users in Ile-de-France and in the province.


Description:

The target population is the population of people living with HIV (PLHIV) (n=18,500) and PrEP users (n=4930) followed up in Parisian infectious and tropical diseases departments (SMIT) of the Pitié-Salpêtrière, Tenon, Saint-Antoine, Bichat, Saint-Louis, Necker hospitals, the University Department of Infectious and Traveller Diseases of Hôpital Dron (Tourcoing), the 190 health center, and the Maison de santé du Chemin vert (Paris). The principal objective is to determine the seroprevalence of Monkeypox infection in the population of PLHIV and PrEP users followed in the infectious and tropical disease departments in 9 centers. In addition to the primary objective, there exist the following secondary objectives: - To assess the level of anti-Mpox antibodies in PLHIV and PrEP users - To assess the level of anti-Mpox antibodies in PLHIV and PrEP users with a previous confirmed diagnosis of Mpox or if they have been recently vaccinated - Assess antibody levels in PLHIV in relation to CD4 cell count and HIV viral load - Study antibody kinetics and persistence over time (D0 (between November 1, 2021 and April 30, 2022), M6, M12) - Study the Mpox seroconversion rate over time - Determine the neutralizing activity of anti-Mpox antibodies in individuals with positive anti-Mpox ELISA serology. - Describe the natural history of the disease, the different forms of the disease, their clinical characterization - Describe sexual behavior and the impact of this health crisis on different aspects of their lives using a self-administered questionnaire - To determine the prevalence of asymptomatic infections - Proportion of participants with positive Mpox serology without PCR confirmed diagnosis - History of childhood or recent smallpox vaccination During the patient's follow-up consultation, after information and in the absence of an expression of no objection, inclusion will consist of recovering a blood sample taken between November 2021 and April 2022 during the HIV infection assessment or PrEP follow-up (no additional sample) and possibly the blood sample taken at M6 and/or M12 if this follow-up consultation has already taken place. An online self-questionnaire will also be proposed to the patient (male only). It will be constructed from questions already validated in other surveys (Rapport au Sexe, Prévenir, Parcours). A check on the appearance or persistence of antibodies will be carried out at M6 +/- 8 weeks and/or M12 +/- 8 weeks on tube bottoms of samples always taken as part of the HIV infection assessment or PrEP follow-up.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 5000
Est. completion date February 1, 2025
Est. primary completion date February 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - People Living with HIV or PrEP users with a blood test within 6 months before the start of the epidemic (i.e. between 1/11/2021 and 30/04/2022, D0) and with a blood test scheduled at M6 and/or at M12 of this collection depending on the care, in the centers participating in the study - Having been informed about the study and not having expressed his opposition - Affiliated to a social security system or entitled person, AME beneficiary Exclusion Criteria: - Refusal of participation by the patient - Under legal protection (guardianship/guardianship) - Not able to understand the information and/or express opposition and/or not speaking French

Study Design


Intervention

Behavioral:
Questionnaire
Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
ANRS, Emerging Infectious Diseases INSERM UMR S 1136, Institut de Recherche en Santé Publique, France, Institut Pasteur

Outcome

Type Measure Description Time frame Safety issue
Primary Mpox serology The primary endpoint will be to determine the presence or not of anti-Mpox antibodies in the population of PLHIV or PrEP users 12 months
Secondary Anti-Mpox antibodies To determine the presence or not of anti-Mpox antibodies by ELISA in PLWHIV and PrEP users with a previous confirmed diagnosis of Mpox or with a recent vaccination 12 months
Secondary Antibody level in PLWHIV Comparison of Mpox serology with CD4 count and viral load of PLHIV 12 months
Secondary Antibody kinetics Comparison of Mpox antibody levels between D0, M6 and M12 12 months
Secondary Mpox seroconversion Comparison of anti-Mpox serology results between D0, M6 and M12 12 months
Secondary Neutralizing activity Observation of the number of serum-neutralization test results for all Mpox-positive samples 12 months
Secondary Natural history of Mpox Collect information on date of seropositivity, date of onset of symptoms, types of symptoms, clinical features of infection. 12 months
Secondary Asymptomatic infections Comparison of the proportion of asymptomatic vs. symptomatic in HIV-positive patients. 12 months
Secondary Mpox serology and PCR Comparison of the proportion of asymptomatic, the proportion with symptoms without PCR confirmation, proportion vaccinated in the past or recently 12 months
Secondary Childhood or recent smallpox vaccination Comparison of proportion with PCR-confirmed Mpox, proportion previously or recently vaccinated. 12 months
Secondary Sexual behavior To count and collection of sexual behavior and impact of health crisis among PLWHIV and PrEP users via self-questionnaire 12 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2